Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT

• Verfasst von: Jensen, Alexandra [VerfasserIn]
• Verfasst von: Krauß, Jürgen [VerfasserIn]
• Verfasst von: Potthoff, Karin [VerfasserIn]
• Verfasst von: Desta, Almaz [VerfasserIn]
• Verfasst von: Habl, Gregor [VerfasserIn]
• Verfasst von: Mavtratzas, Athanasios [VerfasserIn]
• Verfasst von: Windemuth-Kiesselbach, Christine [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Münter, Marc [VerfasserIn]
• Titel: Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT
• Verf.angabe: Alexandra D. Jensen, Jürgen Krauss, Karin Potthoff, Almaz Desta, Gregor Habl, Athanasios Mavtratzas, Christine Windemuth-Kiesselbach, Jürgen Debus and Marc W. Münter
• E-Jahr: 2011
• Jahr: 19 May 2011
• Umfang: 11 S.
• Fussnoten: Gesehen am 05.07.2022
• Titel Quelle: Enthalten in: BMC cancer
• Ort Quelle: London : BioMed Central, 2001
• Jahr Quelle: 2011
• Band/Heft Quelle: 11(2011), Artikel-ID 182, Seite 1-11
• ISSN Quelle: 1471-2407
• DOI: doi:10.1186/1471-2407-11-182
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cetuximab
• Sach-SW: Gross Tumor Volume
• Sach-SW: Induction Chemotherapy
• Sach-SW: Particle Therapy
• Sach-SW: Relative Biologic Effectiveness
• K10plus-PPN: 1809112540

Abstract

Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck (SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by intensification of treatment schedules through introduction of novel induction and combination chemotherapy regimen and altered fractionation regimen, patient tolerance to higher treatment intensities is limited by accompanying side-effects. Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and carbon ion therapy (C12) are able to limit toxicity while maintaining treatment effects. In order to achieve maximum efficacy with yet acceptable toxicity, this sequential phase II trial combines induction chemotherapy with docetaxel, cisplatin, and 5-FU (TPF) followed by radioimmunotherapy with cetuximab as IMRT plus carbon ion boost. We expect this approach to result in increased cure rates with yet manageable accompanying toxicity.